ArticleBMC pregnancy and childbirth2025
Characteristics of lipid metabolism dysfunction in hypertensive disorders of pregnancy.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundHypertensive disorders of pregnancy (HDP) rank among the primary contributors to maternal and perinatal morbidity, characterized by hypertension, proteinuria, and neuropsychiatric manifestations. While metabolic dysfunction is recognized as a driving factor in various diseases, the precise characteristics of lipid metabolism dysfunction in HDP remain inadequately understood.
methodsFull-spectrum metabolomic profiling was performed on peripheral blood samples from 30 patients with HDP and 30 healthy controls, with targeted metabolic validation using placental tissues. RNA sequencing was employed to investigate the molecular characteristics underlying lipid metabolism dysregulation in HDP.
resultsOur findings highlight significant disruptions in lipid metabolism, particularly fatty acyls (FAs), in patients with HDP. The levels of specific FAs were closely associated with HDP clinical characteristics. Furthermore, RNA sequencing revealed a strong correlation between MCAM expression and FA metabolism, as well as HDP-related symptoms. KEGG pathway analysis and molecular biology experiments suggested the activation of MAPK pathway may be related with MCAM's involvement in FA metabolism among patients with HDP.
conclusionsOur study provides insights into the characteristics of lipid metabolism dysfunction in HDP and delineates its potential molecular pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.